Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 195 av 195 resultater
Tid
Selskap
Tittel
Sektor
Kategori
16 Dec 2021
22:00 CET
INVENTIVA
Inventiva annonce sa participation à la « 40th Annual J.P. Morgan Healthcare Conference »
20103010 Biotechnology
Other subject
06 Dec 2021
22:00 CET
INVENTIVA
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
20103010 Biotechnology
Other subject
06 Dec 2021
22:00 CET
INVENTIVA
Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranor
20103010 Biotechnology
Other subject
10 Nov 2021
22:00 CET
INVENTIVA
Inventiva publie ses informations financières du 3ème trimestre 2021
20103010 Biotechnology
Other subject
10 Nov 2021
22:00 CET
INVENTIVA
Inventiva reports 2021 Third Quarter Financial Information
20103010 Biotechnology
Other subject
03 Nov 2021
21:00 CET
INVENTIVA
Inventiva organise un webcast avec des leaders d’opinion à l’occasion du congrès The Liver Meeting™ 2021 de l’AASLD
20103010 Biotechnology
Other subject
03 Nov 2021
21:00 CET
INVENTIVA
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021
20103010 Biotechnology
Other subject
29 Oct 2021
15:29 CEST
INVENTIVA
Inventiva annonce sa participation à plusieurs conférences investisseurs en novembre 2021
20103010 Biotechnology
Other subject
29 Oct 2021
15:29 CEST
INVENTIVA
Inventiva announces participation at several conferences in November 2021
20103010 Biotechnology
Other subject
27 Oct 2021
22:00 CEST
INVENTIVA
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
20103010 Biotechnology
Other subject
27 Oct 2021
22:00 CEST
INVENTIVA
Inventiva annonce le design de LEGEND, un essai clinique de Phase IIa combinant lanifibranor et empagliflozine, un inhibiteur du SGLT2, chez des patients atteints de la NASH et de diabète de type 2
20103010 Biotechnology
Other subject
20 Oct 2021
23:07 CEST
INVENTIVA
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
20103010 Biotechnology
Other subject
20 Oct 2021
23:07 CEST
INVENTIVA
« The New England Journal of Medicine » publie les résultats de l’étude clinique de Phase IIb NATIVE d’Inventiva avec lanifibranor dans la NASH
20103010 Biotechnology
Other subject
18 Oct 2021
22:00 CEST
INVENTIVA
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
20103010 Biotechnology
Other subject
18 Oct 2021
22:00 CEST
INVENTIVA
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
20103010 Biotechnology
Other subject
28 Sep 2021
22:00 CEST
INVENTIVA
Inventiva announces participation at several investor conferences in October 2021
20103010 Biotechnology
Other subject
28 Sep 2021
22:00 CEST
INVENTIVA
Inventiva annonce sa participation à plusieurs conférences investisseurs en octobre 2021
20103010 Biotechnology
Other subject
23 Sep 2021
08:45 CEST
INVENTIVA
Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
20103010 Biotechnology
Other subject
23 Sep 2021
08:45 CEST
INVENTIVA
Inventiva lève 30 millions de dollars dans le cadre de son programme At-The-Market pour des investisseurs institutionnels spécialisés existants et nouveaux
20103010 Biotechnology
Other subject
21 Sep 2021
22:00 CEST
INVENTIVA
Inventiva annonce la décision de la FDA que le statut « Fast Track » accordé à lanifibranor dans la NASH englobe le traitement de la NASH avec cirrhose compensée
20103010 Biotechnology
Other subject
21 Sep 2021
22:00 CEST
INVENTIVA
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
20103010 Biotechnology
Other subject
20 Sep 2021
22:10 CEST
INVENTIVA
Inventiva publie ses résultats financiers du 1er semestre 2021 et fait un point sur ses activités
20103010 Biotechnology
Other financial transaction
20 Sep 2021
22:10 CEST
INVENTIVA
Inventiva reports 2021 first half financial results and provides a corporate update
20103010 Biotechnology
Other financial transaction
16 Sep 2021
22:00 CEST
INVENTIVA
Inventiva annonce des recrutements clés pour accélérer le développement de lanifibranor dans la NASH
20103010 Biotechnology
Other subject
16 Sep 2021
22:00 CEST
INVENTIVA
Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
20103010 Biotechnology
Other subject
10 Sep 2021
15:00 CEST
INVENTIVA
Inventiva’s 2021 First-Half Financial Results Presentation
20103010 Biotechnology
Other subject
10 Sep 2021
15:00 CEST
INVENTIVA
Présentation des résultats financiers du 1er semestre 2021 d’Inventiva
20103010 Biotechnology
Other subject
08 Sep 2021
22:00 CEST
INVENTIVA
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
20103010 Biotechnology
Other subject
08 Sep 2021
22:00 CEST
INVENTIVA
Inventiva annonce le lancement de l’étude clinique pivot de Phase III évaluant lanifibranor dans la NASH
20103010 Biotechnology
Other subject
30 Aug 2021
22:00 CEST
INVENTIVA
Inventiva announces participation at several investor conferences in September 2021
20103010 Biotechnology
Other subject
30 Aug 2021
22:00 CEST
INVENTIVA
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre 2021
20103010 Biotechnology
Other subject
02 Aug 2021
23:00 CEST
INVENTIVA
Inventiva announces the implementation of an At-The-Market program in the United States
20103010 Biotechnology
Other subject
02 Aug 2021
23:00 CEST
INVENTIVA
Inventiva annonce la mise en place d’un programme At-The-Market aux Etats-Unis
20103010 Biotechnology
Other subject
28 Jul 2021
22:00 CEST
INVENTIVA
Inventiva Reports First-Half of 2021 Financial Information
20103010 Biotechnology
Other subject
28 Jul 2021
22:00 CEST
INVENTIVA
Inventiva présente ses informations financières du 1er semestre 2021
20103010 Biotechnology
Other subject
22 Jul 2021
16:00 CEST
INVENTIVA
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
20103010 Biotechnology
Other subject
22 Jul 2021
16:00 CEST
INVENTIVA
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
20103010 Biotechnology
Other subject
15 Jun 2021
22:00 CEST
INVENTIVA
Inventiva annonce sa participation au « SVB Leerink CybeRx Series: Liver Disease Day »
20103010 Biotechnology
Other subject
15 Jun 2021
22:00 CEST
INVENTIVA
Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
20103010 Biotechnology
Other subject
09 Jun 2021
22:00 CEST
INVENTIVA
Inventiva annonce trois présentations scientifiques lors du EASL International Liver Congress™ 2021 et d’un webcast avec des leaders d’opinion
20103010 Biotechnology
Other subject
09 Jun 2021
22:00 CEST
INVENTIVA
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
20103010 Biotechnology
Other subject
25 May 2021
22:00 CEST
INVENTIVA
Inventiva to participate at the Jefferies Virtual Healthcare Conference
20103010 Biotechnology
Other subject
25 May 2021
22:00 CEST
INVENTIVA
Inventiva annonce sa participation à la « Jefferies Virtual Healthcare Conference »
20103010 Biotechnology
Other subject
12 May 2021
22:00 CEST
INVENTIVA
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
20103010 Biotechnology
Other subject
12 May 2021
22:00 CEST
INVENTIVA
Inventiva : information financière du 1er trimestre 2021 et point sur le partenariat avec AbbVie dans le domaine des maladies auto-immunes
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva